Moderate Vaccine Effectiveness against Severe Acute Respiratory Infection Caused by A(H1N1)pdm09 Influenza Virus and No Effectiveness against A(H3N2) Influenza Virus in the 2018/2019 Season in Italy

Vaccines

Daniela Loconsole¹  Maria Chironna¹  Antonino Bella²  Simona Puzelli²  Christian Napoli³  Emanuele Montomoli⁴  GiovanniBattista Orsi⁵  Ilaria Manini⁵  Giulia Guarona⁶  Andrea Orsi⁶  Giancarlo Icardi⁶  Donatella Panatto⁶  Francesco Gesualdo⁷  Elisabetta Pandolfi⁷  Carlo Concato⁷  AlbertoEugenio Tozzi⁷  Alberto Villani⁷  Antonino Reale⁷  MartaLuisaCiofi Degli Atti⁷  Caterina Rizzo⁷  Livia Piccioni⁷  Umberto Raucci⁷  Ilaria Campagna⁷  Luisa Russo⁷  Valeria Alfonsi⁸ 

[1] Department of Biomedical Science and Medical, Oncology of the University of Bari, 70120 Bari, Italy;Department of Infectious Diseases, National Institute of Health, 00161 Rome, Italy;Department of Medical—Surgical Sciences and Translational Medicine, University of Rome “Sapienza”, 00185 Rome, Italy;Department of Molecular and Developmental Medicine, University of Siena, 53100 Siena, Italy;Department of Public Health and Infectious Diseases, Sapienza University of Rome, 00185 Rome, Italy;IRCCS University Hospital San Martino, 16100 Genoa, Italy;IRCCS, Bambino Gesù Children’s Hospital, 00165 Rome, Italy;Medical Direction, University Hospital Sant’Andrea, 00189 Rome, Italy;

关键词: influenza vaccine effectiveness;    test-negative case-control study;    SARI;    Italy;    IT-BIVE-HOSP network;   

DOI  :  10.3390/vaccines8030427

来源: DOAJ

【 摘 要 】

Every season, circulating influenza viruses change; therefore, vaccines must be reformulated each year. We aimed to estimate vaccine effectiveness (VE) against severe influenza infection for the 2018/19 season in Italy. We conducted a test-negative design case-control study at five Italian hospitals. We estimated influenza VE against severe acute respiratory infection (SARI) requiring hospitalisation overall, and by virus subtype, vaccine brand, and age. The 2018/19 season was characterised by A(H1N1)pmd09 and A(H3N2) influenza viruses. Vaccine coverage among <18 years recruited SARI cases was very low (3.2%). Seasonal vaccines were moderately effective against type A influenza overall (adjusted VE = 40.5%; 95% confidence interval (CI) = 18.7–56.4%) and subtype A(H1N1)pmd09 viruses (adjusted VE = 55%; 95% CI = 34.5–69.1%), but ineffective against subtype A(H3N2) viruses (adjusted VE = 2.5%; 95% CI = −50.0–36.7%). Both Fluad and Fluarix Tetra vaccines were effective against type A influenza overall and subtype A(H1N1)pdm09 viruses. VE appeared to be similar across age groups (0–64 years, ≥65 years). Seasonal influenza vaccines in the 2018/19 season were moderately effective in preventing SARI caused by A(H1N1)pdm09 influenza but ineffective against A(H3N2).

【 授权许可】

Unknown